340B drug discounts only amounted to a small percentage of total drugmaker revenue, a hospital-funded study found.
340B Small Share of Drugmaker Revenue, Says Hospital-Backed Report
Despite the increase in the amount of 340B program drug discounts, those only amounted to 3.1% of global and 7% [...]
Please Login or Become a Paid Subscriber to View this Content
If you are already a paid subscriber, please follow the steps below.